Business Context and Reporting Period
This Form 8-K Current Report was filed by Axsome Therapeutics, Inc. on February 10, 2025. The filing addresses a material event under Item 8.01 regarding the resolution of patent litigation concerning the Company's product AUVELITY (dextromethorphan HBr–bupropion HCl).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a legal settlement and does not contain financial statement data.
Material Changes and Events
- Settlement Agreement: Axsome entered into a settlement with Teva Pharmaceuticals, Inc. resolving all patent litigation related to AUVELITY.
- Generic Entry Date: Teva is granted a license to sell a generic version of AUVELITY beginning on or after March 31, 2039, if pediatric exclusivity is granted, or on or after September 30, 2038, if no pediatric exclusivity is granted.
- Conditions: The entry date is subject to FDA approval and customary conditions. All ongoing litigation in the U.S. District Court for the District of New Jersey will be terminated.
- Regulatory Review: The agreement is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance or management commentary on future performance. The primary contingency noted is the requirement for regulatory approval by the FTC and DOJ. The settlement terms are contingent upon the granting of pediatric exclusivity for AUVELITY, which will determine the specific date of generic market entry.
Investor Verification Checklist
- Verify the status of pediatric exclusivity for AUVELITY to confirm the exact generic entry date (2038 vs. 2039).
- Monitor the outcome of the FTC and DOJ review of the settlement agreement.
- Review the full text of the press release (Exhibit 99.1) for any additional terms not summarized in the 8-K.
- Confirm the termination of all pending litigation in the District of New Jersey.